Related Experiment Video

Updated: Jun 19, 2026

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

Bronchial hyperreactivity in non-atopic children with asthma and reflux: effect of anti-reflux treatment

Vikram Khoshoo1, Sopan Mohnot, Robert Haydel

  • 1West Jefferson Medical Center, Marrero, LA 70072, USA. vkhoshoo@sbcglobal.net

Pediatric Pulmonology
|October 16, 2009
PubMed

Insights

Bronchial hyperreactivity (BHR) is common in children with asthma and gastroesophageal reflux disease (GERD). Anti-GERD treatment significantly improves BHR in these pediatric patients.

Area of Science:

  • Pediatric Pulmonology
  • Gastroenterology

Background:

  • Bronchial hyperreactivity (BHR) is a hallmark of asthma.
  • Gastroesophageal reflux disease (GERD) is frequently observed in children with asthma.
  • The relationship between GERD and BHR in pediatric asthma is not well-defined.

Purpose of the Study:

  • To investigate the prevalence of BHR in children with asthma and GERD.
  • To evaluate the impact of anti-GERD treatment on BHR in this population.

Main Methods:

  • Thirty non-atopic children with persistent asthma were enrolled.
  • GERD was diagnosed using extended esophageal pH monitoring.
  • BHR was assessed via methacholine challenge test (MCT) before and 2 years after anti-GERD therapy.

Main Results:

  • Of 21 GERD-positive children, 15 exhibited BHR. Five of 9 GERD-negative children also showed BHR.
  • After 2 years of treatment, BHR resolved in 11 GERD-positive and 3 GERD-negative patients.
  • GERD-positive patients on treatment required fewer asthma medications and experienced fewer exacerbations.

Conclusions:

  • BHR is highly prevalent in children with both asthma and GERD.
  • Effective anti-GERD treatment leads to improvement in BHR.
  • These findings suggest a link between GERD and BHR in pediatric asthma.
Abstract

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

Related Concept Videos

Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...